MedTrace Logo

Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers

NCT00813670 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2009-09-14

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of single and multiple doses of XPF-001 in healthy volunteers.

The effect of food on the pharmacokinetics of XPF-001 will also be studied.

Conditions

  • Healthy Human Volunteers

Interventions

DRUG

XPF-001

Single oral dose, or 6 days of repeated oral doses.

Sponsors & Collaborators

Principal Investigators

  • Richard Larouche, MD · Anapharm

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-05-31
Completion
2009-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00813670 on ClinicalTrials.gov